Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
0.718
+0.008 (1.06%)
At close: Jun 26, 2026, 4:00 PM EDT
0.730
+0.013 (1.74%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Tenaya Therapeutics Employees
Tenaya Therapeutics had 70 employees as of December 31, 2025. The number of employees decreased by 27 or -27.84% compared to the previous year.
Employees
70
Change (1Y)
-27
Growth (1Y)
-27.84%
Revenue / Employee
$3,214
Profits / Employee
-$1,185,786
Market Cap
155.70M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Humacyte | 184 |
| Innate Pharma | 164 |
| Molecular Partners AG | 134 |
| Caribou Biosciences | 97 |
| Milestone Pharmaceuticals | 38 |
| Corbus Pharmaceuticals Holdings | 36 |
| Spruce Biosciences | 14 |
TNYA News
- 23 days ago - Tenaya Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 23 days ago - Tenaya Therapeutics Slides: FY 2026 - Filings
- 24 days ago - Tenaya Therapeutics management to meet with Piper Sandler - TheFly
- 25 days ago - Tenaya Therapeutics Transcript: Study result - Transcripts
- 25 days ago - Tenaya Therapeutics Press release: Study result - Filings
- 25 days ago - Tenaya Therapeutics Slides: Study result - Filings
- 25 days ago - Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - GlobeNewsWire
- 25 days ago - Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - GlobeNewsWire